دورية أكاديمية
أعرض في EDS

Tibial Nerve Stimulation for Urge Urinary Incontinence and Overactive Bladder: Narrative Review of Randomized Controlled Trials and Applicability to Implantable Devices.

التفاصيل البيبلوغرافية
العنوان: Tibial Nerve Stimulation for Urge Urinary Incontinence and Overactive Bladder: Narrative Review of Randomized Controlled Trials and Applicability to Implantable Devices.
المؤلفون: Lee UJ; Virginia Mason Medical Center, 1100 Ninth Ave C7-URO, Seattle, WA, 98101, USA. una.lee@vmfh.org., MacDiarmid S; Alliance Urology Specialists, Greensboro, NC, USA., Matthews CA; Wake Forest Baptist Medical Center, Winston-Salem, NC, USA., Gillespie E; Medtronic, Minneapolis, MN, USA., Peters KM; Corewell Health William Beaumont University Hospital, Royal Oak, MI, USA.
المصدر: Advances in therapy [Adv Ther] 2024 Jul; Vol. 41 (7), pp. 2635-2654. Date of Electronic Publication: 2024 May 15.
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: Health Communications Inc Country of Publication: United States NLM ID: 8611864 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1865-8652 (Electronic) Linking ISSN: 0741238X NLM ISO Abbreviation: Adv Ther Subsets: MEDLINE
أسماء مطبوعة: Publication: New York : Springer Healthcare Communications, 2008- : Health Communications Inc.
Original Publication: Metuchen, N.J. : Health Communications Inc., c1984-
مواضيع طبية MeSH: Tibial Nerve* , Urinary Bladder, Overactive*/therapy , Randomized Controlled Trials as Topic* , Urinary Incontinence, Urge*/therapy, Humans ; Transcutaneous Electric Nerve Stimulation/methods ; Transcutaneous Electric Nerve Stimulation/instrumentation ; Electric Stimulation Therapy/methods ; Electric Stimulation Therapy/instrumentation ; Treatment Outcome ; Female
مستخلص: The tibial nerve is an established target for neuromodulation in the management of overactive bladder (OAB) and its associated symptoms, including urge urinary incontinence (UUI). Technologies are currently available to deliver tibial nerve stimulation (TNS) through percutaneous devices or through implantable devices. The benefits and safety of percutaneous TNS have led to it as a guideline-recommended therapy. However, patient compliance is limited by the burden of weekly office visits and the need for maintenance treatments. Further, insurance often only covers a limited number of lifetime visits for percutaneous TNS. These factors and others have led to the development, study, and utilization of implantable TNS devices. Implantable TNS devices deliver the same therapeutic mechanism of action for nerve stimulation with a permanent implanted device that provides at-home stimulation rather than in-office therapy delivery. Additionally, there is an added potential for dynamic and patient-centered stimulation. There is a large body of high-quality evidence published for TNS, including numerous randomized controlled trials published on percutaneous TNS which have consistently demonstrated superior efficacy to sham and similar efficacy to that of anticholinergic medications. Percutaneous TNS also performs better than conservative therapy including pelvic floor muscle training. The percutaneous and implantable approaches deliver nerve stimulation to the same target nerve, using the same mechanism of action. Therefore, data from randomized trials of percutaneous TNS are informative for implantable TNS devices. At the time of this article's publication, at least two implantable TNS devices have received marketing authorization from the Food and Drug Administration (FDA). The objective of this review is to discuss the mechanism of action for TNS and summarize the published literature from clinical trials of percutaneous TNS as a foundation of high-quality evidence for implantable devices targeting the tibial nerve.
(© 2024. The Author(s), under exclusive licence to Springer Healthcare Ltd., part of Springer Nature.)
References: Haylen BT, de Ridder D, Freeman RM, et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourol Urodyn. 2010;29:4–20. (PMID: 1994127810.1002/nau.20798)
Coyne K, Payne C, Bhattacharyya S, Revicki D, Thompson C, Corey R, Hunt T. The impact of urinary urgency and frequency on health-related quality of life in overactive bladder: results from a national community survey. Value Health J Int Soc Pharmacoecon Outcomes Res. 2004;7:455–63. (PMID: 10.1111/j.1524-4733.2004.74008.x)
Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006;50:1306–15. (PMID: 1704971610.1016/j.eururo.2006.09.019)
Stewart W, Rooyen JV, Cundiff G, Abrams P, Herzog A, Corey R, Hunt T, Wein A. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003;20:327–36. (PMID: 1281149110.1007/s00345-002-0301-4)
Coyne KS, Wein A, Nicholson S, Kvasz M, Chen C-I, Milsom I. Economic burden of urgency urinary incontinence in the United States: a systematic review. J Manag Care Pharm. 2014;20:130–40. (PMID: 24456314)
Elstad EA, Taubenberger SP, Botelho EM, Tennstedt SL. Beyond incontinence: the stigma of other urinary symptoms. J Adv Nurs. 2010;66:2460–70. (PMID: 20735505303226810.1111/j.1365-2648.2010.05422.x)
Aoki Y, Brown H, Brubaker L, Cornu J, Daly J, Cartwright R. Urinary incontinence in women. Nat Rev Dis Primers. 2017;3:17042. (PMID: 28681849587886410.1038/nrdp.2017.42)
D’Ancona C, Haylen B, Oelke M, et al. The International Continence Society (ICS) report on the terminology for adult male lower urinary tract and pelvic floor symptoms and dysfunction. Neurourol Urodyn. 2019;38:433–77. (PMID: 3068118310.1002/nau.23897)
Lightner DJ, Gomelsky A, Souter L, Vasavada SP. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment 2019. J Urol. 2019;202:558–63. (PMID: 3103910310.1097/JU.0000000000000309)
Moskowitz D, Adelstein SA, Lucioni A, Lee UJ, Kobashi KC. Use of third line therapy for overactive bladder in a practice with multiple subspecialty providers—are we doing enough? J Urol. 2018;199:779–84. (PMID: 2896578210.1016/j.juro.2017.09.102)
OCEBM Levels of Evidence Working Group. The Oxford 2011 levels of evidence. Oxford Centre for Evidence-Based Medicine. https://www.cebm.ox.ac.uk/resources/levels-of-evidence/ocebm-levels-of-evidence . Accessed 22 Apr 2024.
Leng WW, Chancellor MB. How sacral nerve stimulation neuromodulation works. Urol Clin North Am. 2005;32:11–8. (PMID: 1569887110.1016/j.ucl.2004.09.004)
de Groat WC. A neurologic basis for the overactive bladder. Urology. 1997;50:36–52. (PMID: 942674910.1016/S0090-4295(97)00587-6)
Al-Danakh A, Safi M, Alradhi M, Almoiliqy M, Chen Q, Al-Nusaif M, Yang X, Al-Dherasi A, Zhu X, Yang D. Posterior tibial nerve stimulation for overactive bladder: mechanism, classification, and management outlines. Parkinson’s Dis. 2022;2022:2700227.
Li X, Li X, Liao L. Mechanism of action of tibial nerve stimulation in the treatment of lower urinary tract dysfunction. Neuromodul Technol Neural Interface. 2023. https://doi.org/10.1016/j.neurom.2023.03.017 . (PMID: 10.1016/j.neurom.2023.03.017)
Tanagho EA, Schmidt RA. Electrical stimulation in the clinical management of the neurogenic bladder. J Urol. 1988;140:1331–9. (PMID: 305722110.1016/S0022-5347(17)42038-6)
Schmidt RA, Jonas U, Oleson KA, Janknegt RA, Hassouna MM, Siegel SW, van Kerrebroeck PEV, van KPEV. Sacral nerve stimulation for treatment of refractory urinary urge incontinence. J Urol. 1999;162:352–7. (PMID: 1041103710.1016/S0022-5347(05)68558-8)
Cooperberg M, Stoller M. Percutaneous neuromodulation. Urol Clin N Am. 2005;32(71–8):vii.
Tai C, Shen B, Chen M, Wang J, Roppolo JR, de Groat WC. Prolonged poststimulation inhibition of bladder activity induced by tibial nerve stimulation in cats. Am J Physiol-Ren Physiol. 2011;300:F385–92. (PMID: 10.1152/ajprenal.00526.2010)
Choudhary M, Mastrigt R, Asselt E. Effect of tibial nerve stimulation on bladder afferent nerve activity in a rat detrusor overactivity model. Int J Urol. 2016;23:253–8. (PMID: 2669055710.1111/iju.13033)
Choudhary M, van Mastrigt R, van Asselt E. Inhibitory effects of tibial nerve stimulation on bladder neurophysiology in rats. Springerplus. 2016;5:35. (PMID: 26835217471340410.1186/s40064-016-1687-6)
Bhide AA, Tailor V, Fernando R, Vik K, Digesu GA. Posterior tibial nerve stimulation for overactive bladder—techniques and efficacy. Int Urogynecol J. 2020;31:865–70. (PMID: 3185359710.1007/s00192-019-04186-3)
Rahnamai MS. Neuromodulation for functional bladder disorders in patients with multiple sclerosis. Mult Scler J. 2020;26:1274–80. (PMID: 10.1177/1352458519894714)
Kobashi K, Nitti V, Margolis E, Sand P, Siegel S, Khandwala S, Newman D, MacDiarmid SA, Kan F, Michaud E. A prospective study to evaluate efficacy using the nuro percutaneous tibial neuromodulation system in drug-naïve patients with overactive bladder syndrome. Urology. 2019;131:77–82. (PMID: 3119996610.1016/j.urology.2019.06.002)
Harding, Lapitan M, Arlandis S et al (2023) EAU guidelines on management of non-neurogenic female lower urinary tract symptoms. https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Non-neurogenic-Female-LUTS-2023.pdf .
Chermansky C, Schurch B, Rahnamai M, Averbeck M, Malde S, Mancini V, Valentini F, Sahai A. How can we better manage drug-resistant OAB/DO? ICI-RS 2018. Neurourol Urodyn. 2019;38(Suppl 5):S46–55. (PMID: 31821628)
Marcelissen T, Cornu J-N, Antunes-Lopes T, Geavlete B, Delongchamps NB, Rashid T, Rieken M, Rahnama’i MS. Management of idiopathic overactive bladder syndrome: what is the optimal strategy after failure of conservative treatment? [Figure presented]. Eur Urol Focus. 2018;4:760–7. (PMID: 2980782310.1016/j.euf.2018.05.004)
Apostolidis A, Averbeck M, Sahai A, Rahnama’i M, Anding R, Robinson D, Gravas S, Dmochowski R. Can we create a valid treatment algorithm for patients with drug resistant overactive bladder (OAB) syndrome or detrusor overactivity (DO)? Results from a think tank (ICI-RS 2015). Neurourol Urodyn. 2017;36:882–93. (PMID: 2844470810.1002/nau.23170)
Gordon T, Merchant M, Ramm O, Patel M. Factors associated with long-term use of percutaneous tibial nerve stimulation for management of overactive bladder syndrome. Female Pelvic Med Reconstr Surg. 2021;27:444–9. (PMID: 3264932510.1097/SPV.0000000000000911)
Jung CE, Menefee SA, Diwadkar GB. Percutaneous tibial nerve stimulation maintenance therapy for overactive bladder in women: long-term success rates and adherence. Int Urogynecol J. 2021;32:617–25. (PMID: 3257254110.1007/s00192-020-04325-1)
te DMJ, J.P.F.A. H, van BMR. Long-term real-life adherence of percutaneous tibial nerve stimulation in over 400 patients. Neurourol Urodyn. 2020;39:702–6.
Chapple CR, Nazir J, Hakimi Z, Bowditch S, Fatoye F, Guelfucci F, Khemiri A, Siddiqui E, Wagg A. Persistence and adherence with mirabegron versus antimuscarinic agents in patients with overactive bladder: a retrospective observational study in UK clinical practice. Eur Urol. 2017;72:389–99. (PMID: 2819672410.1016/j.eururo.2017.01.037)
Yeowell G, Smith P, Nazir J, Hakimi Z, Siddiqui E, Fatoye F. Real-world persistence and adherence to oral antimuscarinics and mirabegron in patients with overactive bladder (OAB): a systematic literature review. BMJ Open. 2018. https://doi.org/10.1136/bmjopen-2018-021889 . (PMID: 10.1136/bmjopen-2018-021889304671316252764)
Michel MC, Cardozo L, Chermansky CJ, Cruz F, Igawa Y, Lee K-S, Sahai A, Wein AJ, Andersson K-E. Current and emerging pharmacological targets and treatments of urinary incontinence and related disorders. Pharmacol Rev. 2023;75:PHARMREV-AR-2021-000523.
eCoin summary of safety and effectiveness data. https://www.accessdata.fda.gov/cdrh_docs/pdf20/P200036B.pdf . Accessed 1 Dec 2023.
eCoin physician manual. https://www.accessdata.fda.gov/cdrh_docs/pdf20/P200036D.pdf . Accessed 1 Dec 2023.
ReviTM patient therapy guide. https://bluewindmedical.com/wp-content/uploads/2023/10/revi-patient-therapy-guide.pdf . Accessed 28 Nov 2023.
Rogers A, Bragg S, Ferrante K, Thenuwara C, Peterson DKL. Pivotal study of leadless tibial nerve stimulation with eCoin ® for urgency urinary incontinence: an open-label, single arm trial. J Urol. 2021;206:399–408. (PMID: 3379729110.1097/JU.0000000000001733)
Lee UJ, Xavier K, Benson K, et al. Rationale and design of an implant procedure and pivotal study to evaluate safety and effectiveness of Medtronic’s tibial neuromodulation device. Contemp Clin Trials Commun. 2023;35: 101198. (PMID: 376918491049163010.1016/j.conctc.2023.101198)
Govier F, Litwiller S, Nitti V, Kreder Jr K, Rosenblatt P. Percutaneous afferent neuromodulation for the refractory overactive bladder: results of a multicenter study. J Urol. 2001;165:1193–8. (PMID: 1125766910.1016/S0022-5347(05)66469-5)
eCoin peripheral neurostimulator system patient manual. https://www.accessdata.fda.gov/cdrh_docs/pdf20/P200036C.pdf . Accessed 28 Nov 2023.
Finazzi-Agrò E, Rocchi C, Pachatz C, Petta F, Spera E, Mori F, Sciobica F, Marfia GA. Percutaneous tibial nerve stimulation produces effects on brain activity: study on the modifications of the long latency somatosensory evoked potentials. Neurourol Urodyn. 2009;28:320–4. (PMID: 1909058810.1002/nau.20651)
Peters KM, Carrico DJ, Perez-Marrero RA, Khan AU, Wooldridge LS, Davis GL, MacDiarmid SA. Randomized trial of percutaneous tibial nerve stimulation versus sham efficacy in the treatment of overactive bladder syndrome: results from the SUmiT trial. J Urol. 2010;183:1438–43. (PMID: 2017167710.1016/j.juro.2009.12.036)
Finazzi-Agr E, Petta F, Sciobica F, Pasqualetti P, Musco S, Bove P. Percutaneous tibial nerve stimulation effects on detrusor overactivity incontinence are not due to a placebo effect: a randomized, double-blind, placebo controlled trial. J Urol. 2010;184:2001–6. (PMID: 10.1016/j.juro.2010.06.113)
Lashin A, Eltabey N, Wadie B. Percutaneous tibial nerve stimulation versus sham efficacy in the treatment of refractory overactive bladder: outcomes following a shortened 6-week protocol, a prospective randomized controlled trial. Int Urol Nephrol. 2021;53:2459–67. (PMID: 3460170510.1007/s11255-021-02999-0)
Scaldazza CV, Morosetti C, Giampieretti R, Lorenzetti R, Baroni M, Italy A. Percutaneous tibial nerve stimulation versus electrical stimulation with pelvic floor muscle training for overactive bladder syndrome in women: results of a randomized controlled study. Int Braz J Urol. 2016;43:121–6. (PMID: 10.1590/s1677-5538.ibju.2015.0719)
Peters KM, MacDiarmid SA, Wooldridge LS, et al. Randomized trial of percutaneous tibial nerve stimulation versus extended-release tolterodine: results from the overactive bladder innovative therapy trial. J Urol. 2009;182:1055–61. (PMID: 1961680210.1016/j.juro.2009.05.045)
Vecchioli-Scaldazza C, Morosetti C, Berouz A, Giannubilo W, Ferrara V. Solifenacin succinate versus percutaneous tibial nerve stimulation in women with overactive bladder syndrome: results of a randomized controlled crossover study. Gynecol Obstet Investig. 2013;75:230–4. (PMID: 10.1159/000350216)
Preyer O, Umek W, Laml T, Bjelic-Radisic V, Gabriel B, Mittlboeck M, Hanzal E. Percutaneous tibial nerve stimulation versus tolterodine for overactive bladder in women: a randomised controlled trial. Eur J Obstet Gynecol Reprod Biol. 2015;191:51–6. (PMID: 2607326210.1016/j.ejogrb.2015.05.014)
Vecchioli-Scaldazza C, Morosetti C. Effectiveness and durability of solifenacin versus percutaneous tibial nerve stimulation versus their combination for the treatment of women with overactive bladder syndrome: a randomized controlled study with a follow-up of ten months. Int Braz J Urol Off J Braz Soc Urol. 2018;44:102–8. (PMID: 10.1590/s1677-5538.ibju.2016.0611)
Sherif H, Khalil M, Omar R. Management of refractory idiopathic overactive bladder: intradetrusor injection of botulinum toxin type A versus posterior tibial nerve stimulation. Can J Urol. 2017;24:8838–46. (PMID: 28646940)
MacDiarmid S, Staskin DR, Lucente V, et al. Feasibility of a fully-implanted, nickel-sized and shaped tibial nerve stimulator for the treatment of overactive bladder syndrome with urgency urinary incontinence. J Urol. 2019;201:967–72. (PMID: 3100996810.1016/j.juro.2018.10.017)
Ghavidel-Sardsahra A, Ghojazadeh M, Rahnama’I M, et al. Efficacy of percutaneous and transcutaneous posterior tibial nerve stimulation on idiopathic overactive bladder and interstitial cystitis/painful bladder syndrome: a systematic review and meta-analysis. Neurourol Urodyn. 2022;41:539–51. (PMID: 3503232810.1002/nau.24864)
Gray S, Anderson M, Dublin S, Hanlon J, Hubbard R, Walker R, Yu O, Crane P, Larson E. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. JAMA Intern Med. 2015;175:401–7. (PMID: 25621434435875910.1001/jamainternmed.2014.7663)
An F, Yang X, Wang Y, Chen J, Wang J. OAB epidemiological survey of general gynaecology outpatients and its effects on patient quality of life. Neurourol Urodyn. 2016;35:29–35. (PMID: 2530753410.1002/nau.22659)
Zillioux J, Welk B, Suskind A, Gormley E, Goldman H. SUFU white paper on overactive bladder anticholinergic medications and dementia risk. Neurourol Urodyn. 2022;41:1928–33. (PMID: 3606604610.1002/nau.25037)
Du C, Berg W, Siegal A, Huang Z, Jeong R, Hwang K, Kim J. Real-world compliance with percutaneous tibial nerve stimulation maintenance therapy in an American population. Urology. 2021;153:119–23. (PMID: 3358123210.1016/j.urology.2021.02.005)
Malde S, Marcelissen T, Vrijens D, Apostilidis A, Rahnama’I S, Cardozo L, Lovick T. Sacral nerve stimulation for refractory OAB and idiopathic urinary retention: can phenotyping improve the outcome for patients: ICI-RS 2019? Neurourol Urodyn. 2020;39(Suppl 3):S96–103. (PMID: 32662561)
فهرسة مساهمة: Keywords: Implantable tibial nerve stimulation devices; Neurostimulation; Overactive bladder; Percutaneous tibial nerve stimulation; Tibial nerve stimulation; Urge urinary incontinence
تواريخ الأحداث: Date Created: 20240515 Date Completed: 20240628 Latest Revision: 20240628
رمز التحديث: 20240628
DOI: 10.1007/s12325-024-02864-3
PMID: 38748331
قاعدة البيانات: MEDLINE
الوصف
تدمد:1865-8652
DOI:10.1007/s12325-024-02864-3